港通医疗
(301515)
| 流通市值：12.68亿 | | | 总市值：18.77亿 |
| 流通股本：6755.76万 | | | 总股本：1.00亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 272,557,561.17 | 50,485,892.96 | 721,613,692.59 | 344,363,431.23 |
| 营业收入 | 272,557,561.17 | 50,485,892.96 | 721,613,692.59 | 344,363,431.23 |
| 利息收入 | 0 | - | - | - |
| 已赚保费 | 0 | - | - | - |
| 手续费及佣金收入 | 0 | - | - | - |
| 二、营业总成本 | 279,999,205.95 | 62,319,573.87 | 665,991,785.18 | 342,076,025.87 |
| 营业成本 | 226,655,765.75 | 42,126,661.89 | 558,118,545.8 | 267,049,285.19 |
| 利息支出 | 0 | - | - | - |
| 手续费及佣金支出 | 0 | - | - | - |
| 退保金 | 0 | - | - | - |
| 赔付支出净额 | 0 | - | - | - |
| 提取保险合同准备金净额 | 0 | - | - | - |
| 保单红利支出 | 0 | - | - | - |
| 分保费用 | 0 | - | - | - |
| 税金及附加 | 2,414,247.06 | 642,844.88 | 5,816,419.02 | 3,692,053.17 |
| 销售费用 | 19,025,423.4 | 6,352,457.73 | 38,901,382.51 | 29,855,978.36 |
| 管理费用 | 20,419,121.75 | 9,162,878.79 | 36,446,449.25 | 26,554,651.14 |
| 研发费用 | 10,187,086.88 | 3,804,100.75 | 25,993,152.8 | 14,381,647.71 |
| 财务费用 | 1,297,561.11 | 230,629.83 | 715,835.8 | 542,410.3 |
| 其中:利息费用 | 3,419,114.24 | 1,503,566.55 | 6,347,296.02 | 4,771,565.03 |
| 其中:利息收入 | 2,750,579.22 | 1,457,388.4 | 6,297,553.95 | 4,579,309.09 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 0 | - | - | 511,856.85 |
| 加:投资收益 | -73,967.94 | - | 200,049.07 | -179,385.42 |
| 净敞口套期收益 | 0 | - | - | - |
| 汇兑收益 | 0 | - | - | - |
| 资产处置收益 | 122,858.91 | 41,557.7 | 142,830.32 | 114,157.19 |
| 资产减值损失(新) | -3,003,722.86 | -134,614.23 | -4,456,420.43 | -1,614,316.75 |
| 信用减值损失(新) | -16,061,631.5 | 9,716,221.28 | -65,544,214.61 | -19,080,939.17 |
| 其他收益 | 1,840,401.73 | 411,595.12 | 4,832,667.87 | 2,219,863.32 |
| 四、营业利润 | -24,617,706.44 | -1,798,921.04 | -9,203,180.37 | -15,741,358.62 |
| 加:营业外收入 | 730,094.78 | 22,798.11 | 963,995.16 | 404,915.31 |
| 减:营业外支出 | 17,430.08 | 14,372.15 | 460,892.02 | 116,484.05 |
| 五、利润总额 | -23,905,041.74 | -1,790,495.08 | -8,700,077.23 | -15,452,927.36 |
| 减:所得税费用 | -4,076,786.75 | -305,726.71 | -3,521,294.29 | -3,616,309.55 |
| 六、净利润 | -19,828,254.99 | -1,484,768.37 | -5,178,782.94 | -11,836,617.81 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -19,828,254.99 | -1,484,768.37 | -5,178,782.94 | -11,836,617.81 |
| 终止经营净利润 | 0 | - | - | - |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -18,351,221.3 | -662,873.3 | -2,645,330.24 | -10,208,398.36 |
| 少数股东损益 | -1,477,033.69 | -821,895.07 | -2,533,452.7 | -1,628,219.45 |
| 扣除非经常损益后的净利润 | -21,368,497.74 | -1,478,586.35 | -10,005,872.6 | -12,865,150.31 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.19 | -0.01 | -0.03 | -0.11 |
| (二)稀释每股收益 | -0.19 | -0.01 | -0.03 | -0.11 |
| 八、其他综合收益 | -80,668.23 | - | -89,274.2 | -97,891.78 |
| 归属于母公司股东的其他综合收益 | -80,668.23 | - | -89,274.2 | -97,891.78 |
| 九、综合收益总额 | -19,908,923.22 | -1,484,768.37 | -5,268,057.14 | -11,934,509.59 |
| 归属于母公司股东的综合收益总额 | -18,431,889.53 | -662,873.3 | -2,734,604.44 | -10,306,290.14 |
| 归属于少数股东的综合收益总额 | -1,477,033.69 | -821,895.07 | -2,533,452.7 | -1,628,219.45 |
| 公告日期 | 2026-08-28 | 2026-04-24 | 2026-04-24 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |